You are here: Industry Insights > AGC Biologics

News List

AGC Biologics Appoints GM at Boulder Facility contractpharma
January 19, 2022
Regina Choi-Rivera brings more than 25 years of experience in the biotech industry.
AGC Biologics to increase capacity for pDNA and mRNA manufacturing in Heidelberg cphi-online
September 23, 2021
The expansion plans include an additional manufacturing line, a new cleanroom and a new process development lab
AGC Biologics Appoints Jun Takami GM of Chiba Site contractpharma
April 09, 2021
Mr. Takami brings more than 15 years of experience in the pharmaceutical industry.
AGC Biologics Manufactures Orchard Therapeutics' Libmeldy contractpharma
January 05, 2021
European Commission approves one-time therapy for early-onset Metachromatic Leukodystrophy, manufactured at AGC's Milan facility.
Pierre Fabre Selects AGC Biologics as CDMO to manufacture the orphan drug ER-004 prnasia
December 22, 2020
AGC Biologics announced its partnership with Laboratoire Pierre Fabre to manufacture ER-004 – an intra-amniotic drug that will pioneer the treatment of a rare and debilitating genetic disorder.
AGC Biologics Expands Copenhagen Facility contractpharma
December 07, 2020
AGC Biologics is increasing the production capacity of its Copenhagen facility. The company will construct a new building on land adjacent to its current Copenhagen site, adding production floors with 2000L single-use bioreactors, labs and office space.
AGC Biologics to Expand Biopharmaceutical CDMO Capacity prnasia
December 01, 2020
AGC Biologics announced that it will increase the production capacity of its Copenhagen facility. AGC Biologics will construct a new building on land adjacent to its current Copenhagen site, adding production floors with 2000L single-use bioreactors ...
AGC Biologics and Horizon Therapeutics plc Expand Partnership prnasia
October 30, 2020
AGC Biologics, a leading global biopharmaceutical Contract Development and Manufacturing Organization (CDMO), announced that its partnership with Horizon Therapeutics plc is expanding to produce Horizon's Thyroid Eye Disease (TED) treatment ...
MolMed S.p.A Becomes AGC Biologics S.p.A Following the July Acquisition prnasia
October 29, 2020
After its parent company AGC Inc. acquired 100% of the shares of MolMed S.p.A. on September 30, 2020, AGC Biologics announced that MolMed's entity name has been changed to AGC Biologics S.p.A.
AGC Biologics Appoints New GM of Milan Site contractpharma
October 14, 2020
Luca Alberici will initiate integration efforts resulting from the July 2020 acquisition of MolMed.

Previous page 1 2 3 4 Next page